$1.90
8.65% day before yesterday
Nasdaq, Dec 20, 10:15 pm CET
ISIN
US09074F2074
Symbol
BIVI
Sector
Industry

BioVie Inc Stock price

$1.90
-1.46 43.45% 1M
-2.74 59.05% 6M
-10.70 84.92% YTD
-11.00 85.27% 1Y
-45.50 95.99% 3Y
-43.10 95.78% 5Y
-338.10 99.44% 10Y
Nasdaq, Closing price Fri, Dec 20 2024
-0.18 8.65%
ISIN
US09074F2074
Symbol
BIVI
Sector
Industry

Key metrics

Market capitalization $33.76m
Enterprise Value $17.46m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.07
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-25.43m
Free Cash Flow (TTM) Free Cash Flow $-19.35m
Cash position $20.02m
EPS (TTM) EPS $-5.70
Short interest 12.52%
Show more

Is BioVie Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

BioVie Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BioVie Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BioVie Inc:

Buy
100%

Financial data from BioVie Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.23 0.23
15% 15%
-
-0.23 -0.23
15% 15%
-
- Selling and Administrative Expenses 8.76 8.76
22% 22%
-
- Research and Development Expense 16 16
54% 54%
-
-25 -25
46% 46%
-
- Depreciation and Amortization 0.23 0.23
15% 15%
-
EBIT (Operating Income) EBIT -25 -25
46% 46%
-
Net Profit -26 -26
49% 49%
-

In millions USD.

Don't miss a Thing! We will send you all news about BioVie Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioVie Inc Stock News

Neutral
GlobeNewsWire
about 2 months ago
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at...
Neutral
GlobeNewsWire
about 2 months ago
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at...
Neutral
GlobeNewsWire
about 2 months ago
CARSON CITY, Nev., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 2,667,000 shares of its...
More BioVie Inc News

Company Profile

BioVie, Inc. is a development stage biopharmaceutical company, which discovers, develops, and commercializes drug therapies for liver disease. It focuses on BIV201 which treats ascites due to chronic liver cirrhosis. The company was founded on April 10, 2013 and is headquartered in Santa Monica, CA.

Head office United States
CEO Cuong Do
Employees 14
Founded 2013
Website www.bioviepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today